- Faculty
- BR1DGE
Colin Dayan
Professor of Clinical Diabetes and Metabolism Diabetes Research Group, Cardiff University School of Medicine, Cardiff, UK
.svg)
If we treat T1D as an autoimmune disease and not as a metabolic disease, we can eventually make the use of insulin in T1D a relic of the past
Professor Colin Dayan trained in medicine at University College, Oxford, and Guy’s and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves’ Disease in the Laboratory of Marc Feldmann.
He then spent a year as an endocrine fellow at the Massachusetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford.
Professor Dayan has a long-established interest in translational research in the immunopathology of type 1 diabetes promoting progress to “insulin-free T1D”. He has published first-in-man clinical studies on the development of peptide immunotherapy and the use of nanoparticles in T1D as well as pioneering the use of lymph node and injection site sampling to monitor the response to therapy. Since 2015 he has been a leading member of the UKT1D-Research Consortium which has hosted more than 15 clinical trials in early T1D over 30 sites.
